Cargando…
The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709794/ https://www.ncbi.nlm.nih.gov/pubmed/31686912 http://dx.doi.org/10.2147/CMAR.S219237 |
_version_ | 1783446242112569344 |
---|---|
author | Wang, Manni Wu, Shuang Tong, An Cui, Xiwei Ma, Xuelei |
author_facet | Wang, Manni Wu, Shuang Tong, An Cui, Xiwei Ma, Xuelei |
author_sort | Wang, Manni |
collection | PubMed |
description | BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma. METHODS: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival. RESULTS: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, p=0.003) were selected as independent prognostic factors. CONCLUSION: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS. |
format | Online Article Text |
id | pubmed-6709794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67097942019-11-04 The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma Wang, Manni Wu, Shuang Tong, An Cui, Xiwei Ma, Xuelei Cancer Manag Res Original Research BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma. METHODS: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival. RESULTS: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, p=0.003) were selected as independent prognostic factors. CONCLUSION: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS. Dove 2019-08-22 /pmc/articles/PMC6709794/ /pubmed/31686912 http://dx.doi.org/10.2147/CMAR.S219237 Text en © 2019 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Manni Wu, Shuang Tong, An Cui, Xiwei Ma, Xuelei The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title | The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title_full | The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title_fullStr | The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title_full_unstemmed | The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title_short | The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
title_sort | prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709794/ https://www.ncbi.nlm.nih.gov/pubmed/31686912 http://dx.doi.org/10.2147/CMAR.S219237 |
work_keys_str_mv | AT wangmanni theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT wushuang theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT tongan theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT cuixiwei theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT maxuelei theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT wangmanni prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT wushuang prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT tongan prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT cuixiwei prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma AT maxuelei prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma |